| 项目编号 |
PRJCA016620 |
| 项目标题 |
Molecular mechanism of drug-resistant microenvironment in ovarian cancer |
| 涉及领域 |
Medical |
| 数据类型 |
Transcriptome or Gene expression
Raw sequence reads
Single cell sequencing
Data and atlas of clinical cohort, cell and animal
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Ovarian cancer is a serious gynecological malignancy that poses a significant threat to women's life and health, and China has the highest number of patients worldwide. Ovarian cancer is difficult to diagnose early due to lacking symptoms, difficult to classify due to complex types, and difficult to treat due to drug resistance and recurrent. As a result, the 5-year overall survival rate has remained between 30% ~ 40% for over a century. It severely impedes the accomplishment of the arduous task proposed by President Xi that increasing the 5-year survival rate of cancer by 15%, as outlined in the "Healthy China 2030 Plan". Based on the clinic trial NeoAdjuvant Niraparib Therapy (NANT, identifier: NCT04507841), here we investigate the effects of genetic background, tumor microenvironment and their interactions on PARP inhibitor resistance of ovarian cancer through multi omics sequencing. |
| 样品范围 |
Multispecies |
| 发布日期 |
2025-04-27 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 39366751
|
PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancer
|
Journal for Immunotherapy of Cancer
|
10.1136/jitc-2024-009032
|
2024
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Ministry of Science and Technology of the People's Republic of China (MOST)
|
|
2022YFC2704200
|
Mechanism, precise prevention and therapy of ovarian cancer
|
| Ministry of Science and Technology of the People's Republic of China (MOST)
|
|
2022YFC2704203
|
Molecular mechanism of drug-resistant microenvironment in ovarian cancer
|
|
| 提交者 |
Qinglei
Gao (qingleigao@hotmail.com)
|
| 提交单位 |
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 提交日期 |
2023-04-18 |